The Global Platform for Preventing Type 1 Diabetes - GPPAD (original) (raw)
THE GLOBAL PLATFORM FOR THE
PREVENTION OF AUTOIMMUNE DIABETES (GPPAD)
RESEARCH FOR A WORLD
WITHOUT TYPE 1 DIABETES
Joint Effort across Europe.
Welcome to our Sites.
Dr. Agnieszka Szypowska | Warszawa, Poland
Prof. Dr. Helena Elding Larsson | Malmö, Sweden
Prof. Dr. Kristina Casteels | Leuven, Belgium
Dr. Mariusz Ołtarzewski | Warszawa, Poland
Prof. Dr. Anette-Gabriele Ziegler | Munich, Germany
Prof. Dr. Steve Robson | Newcastle, UK
Prof. Dr. Ezio Bonifacio | Saxony, Germany
Prof. Dr. Markus Lundgren | Malmö, Sweden
Prof. Dr. Olga Kordonouri | Hanover, Germany
WHAT IS GPPAD?
Preventing Type 1 Diabetes together.
The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) was established in 2017 as a consortium of European research institutions. It aims to facilitate a coordinated, multidisciplinary approach to genetic screening and the conduct of primary prevention studies for type 1 diabetes. The overarching goal of GPPAD studies is to significantly reduce the incidence of islet autoimmunity and type 1 diabetes in children. To achieve this, clinical research sites from Belgium (Leuven), Germany (Dresden, Hanover, Munich), Poland (Warsaw), Sweden (Malmö), the United Kingdom (Oxford, Cambridge, Newcastle), and Austria (Vienna) collaborate.
OVER 600,000 EUROPEAN CHILDREN ARE IN.
Our Screenings and Studies.
GPPAD conducts newborn screening in the general population to identify infants at high genetic risk of developing islet autoimmunity and type 1 diabetes. GPPAD investigators provide expert counseling to these families and invites them to participate in primary prevention studies. To date, over 600,000 infants have undergone screening, and more than 2,400 children are participating in the GPPAD prevention studies, POInT, SINT1A, and AVAnT1A. GPPAD also encompasses expert groups for celiac disease and allergy research.
SHARING DATA TO DRIVE INNOVATIONS.
Repository for biospecimen and data.
Furthermore, GPPAD provides researchers worldwide with the opportunity to conduct innovative research on biospecimens from the GPPAD studies, aiming to make significant advances in the study of the etiology, pathogenesis, and prevention of type 1 diabetes and other immune-mediated diseases.
JOINT EUROPEAN EFFORT.
Coordinated from Munich.
The GPPAD coordination center is situated at the Institute of Diabetes Research at Helmholtz Munich, with the Klinikum rechts der Isar of the Technical University of Munich acting as the sponsor for clinical trials in GPPAD.